Table 1. Characteristics of the study participants.
Characteristic | All survivors (n=123) |
---|---|
Age at TBI, y, median (range) | 11.8 (1.6, 21.9) |
Age at last followup, y, median (range) | 20.1 (4.0, 41.3) |
Follow-up since TBI, y, median (range) | 8.0 (1.01, 24.6) |
Sex, no. (%) | |
Male | 77 (62.6) |
Female | 46 (37.3) |
Race, no. (%) | |
White, non-Hispanic | 96 (78.0) |
Other | 23 (18.6) |
No response | 4 (0.03) |
TBI dose (cGy), no. (%) | |
Range | 12–15 Gy |
≤ 1410 | 54 (43.9) |
> 1410 | 69 (56.1) |
Primary diagnosis, no. (%) | |
ALL/NHL | 77 (62.6) |
AML/CML | 46 (37.4) |
Pre-transplant therapy, no. (%) | |
Anthracyclines | 115 (93.5) |
Glucocorticoids* | 100 (81.3) |
Cranial radiotherapy | 38 (30.9) |
Pre-transplant BMI, no. (%) | |
Obese | 20 (16.3) |
Non-obese | 103 (83.7) |
HCT type, no. (%) | |
Autologous | 5 (4.1) |
Allogeneic | 118 (95.9) |
Graft source, no. (%) | |
Bone marrow (BM) | 86 (69.9) |
Peripheral blood stem cells (PBSC) | 27 (21.9) |
Cord blood | 8 (6.5) |
BM + Cord | 1 (0.8) |
BM + PBSC | 1 (0.8) |
Donor source, allogeneic transplants only, no. (%) | |
Related | 59 (50.0) |
Unrelated | 59 (50.0) |
GVHD Prophylaxis**, allogeneic transplants only, no. (%) | |
T-cell depletion | 77 (65.3) |
Cyclosporine | 35 (29.7) |
Methotrexate | 28 (23.7) |
Mycophenolate mofetil | 8 (6.7) |
Corticosteroids | 6 (5.2) |
Tacrolimus | 5 (4.3) |
Sirolimus | 1 (0.9) |
Acute GVHD, allogeneic transplants only, no. (%) | |
Grade I or none | 104 (88.1) |
Grade II-IV | 14 (11.8) |
Chronic GVHD, allogeneic transplants only, no. (%) | |
No | 107 (90.7) |
Yes | 11 (9.3) |
Abbreviations: y indicates years; HCT, hematopoietic stem cell transplant; TBI, total body irradiation; ALL, acute lymphoblastic leukemia; NHL, non-Hodgkin lymphoma; AML, acute myelogenous leukemia; CML, chronic myelogenous leukemia; and GVHD, graft-versus-host disease.
Refers to glucocorticoids used for upfront chemotherapy;
Numbers do not sum to 100 percent since most allogeneic HCT recipients received more than one agent for GVHD prophylaxis